<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JPP</journal-id>
<journal-id journal-id-type="hwp">spjpp</journal-id>
<journal-title>Journal of Pharmacy Practice</journal-title>
<issn pub-type="ppub">0897-1900</issn>
<issn pub-type="epub">1531-1937</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0897190012442717</article-id>
<article-id pub-id-type="publisher-id">10.1177_0897190012442717</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Adverse Drug Event</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Suspected Methotrexate Toxicity From Omeprazole</article-title>
<subtitle>A Case Review of Carboxypeptidase G2 Use in a Methotrexate-Experienced Patient With Methotrexate Toxicity and a Review of the Literature</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>McBride</surname>
<given-names>Ali</given-names>
</name>
<degrees>PharmD, MS, BCPS</degrees>
<xref ref-type="aff" rid="aff1-0897190012442717">1</xref>
<xref ref-type="corresp" rid="corresp1-0897190012442717"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Antonia</surname>
<given-names>Scott J.</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff2-0897190012442717">2</xref>
<xref ref-type="aff" rid="aff3-0897190012442717">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Haura</surname>
<given-names>Eric B.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0897190012442717">2</xref>
<xref ref-type="aff" rid="aff3-0897190012442717">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Goetz</surname>
<given-names>Dawn</given-names>
</name>
<degrees>PharmD</degrees>
<xref ref-type="aff" rid="aff4-0897190012442717">4</xref>
</contrib>
</contrib-group>
<aff id="aff1-0897190012442717"><label>1</label>Department of Pharmacy, The Ohio State University, Columbus, OH</aff>
<aff id="aff2-0897190012442717"><label>2</label>Thoracic Oncology and Experimental Therapeutics Programs, HLee Moffitt Cancer Center and Research Institute, Tampa, FL, USA</aff>
<aff id="aff3-0897190012442717"><label>3</label>Department of Interdisciplinary Oncology, University of South Florida College of Medicine, Tampa, FL, USA</aff>
<aff id="aff4-0897190012442717"><label>4</label>Pharmacy, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA</aff>
<author-notes>
<corresp id="corresp1-0897190012442717">Ali McBride PharmD, MS, BCPS, Specialty Practice Pharmacist, Stem Cell Transplant, Arthur G. James Cancer Hospital, The Ohio State University, Department of Pharmacy, Room 368, Doan Hall, Columbus, OH, 43210 Email: <email>alimcbride@gmail.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2012</year>
</pub-date>
<volume>25</volume>
<issue>4</issue>
<fpage>477</fpage>
<lpage>485</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25-year-old man with osteosarcoma. The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ulcer prophylaxis, and it was discontinued before the start of the first day of the patient’s second round of high-dose methotrexate. The 24-hour methotrexate level was elevated and he continued to have sustained levels for 18 days. Side effects due to elevated serum methotrexate included seizures, mucositis, acute renal failure, and thrombocytopenia. Aggressive hydration, urinary alkalinization, and leucovorin were continued during the period of elevated methotrexate levels, with the patient receiving a course of hemodialysis and a dose of carboxypeptidase G2. The patient’s symptoms resolved, and his renal function returned to baseline within 2 months. The patient was able to receive future courses of chemotherapy without methotrexate. Although use of the Naranjo adverse reaction probability scale indicated a probable relationship (score of 6) between the patient’s development of methotrexate toxicity and omeprazole use, we believe this was a drug-drug interaction case consistent with previous reports in the literature.</p>
</abstract>
<kwd-group>
<kwd>omeprazole</kwd>
<kwd>high-dose methotrexate</kwd>
<kwd>chemotherapy</kwd>
<kwd>renal failure</kwd>
<kwd>toxicity carboxypeptidase G2</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0897190012442717">
<title>Introduction</title>
<p>Methotrexate has been used to treat pediatric malignancies since the late 1940s.<sup>
<xref ref-type="bibr" rid="bibr1-0897190012442717">1</xref>
</sup> Its mechanism of action as an inhibitor of DNA replication has been used in a variety of disease states including psoriasis and rheumatoid arthritis and as part of chemotherapy regimens for leukemia, lymphoma, and sarcoma.<sup>
<xref ref-type="bibr" rid="bibr2-0897190012442717">2</xref>
</sup> The effectiveness of these treatments depends on the ability of methotrexate and its active metabolites to compete for binding sites on the enzyme dihydrofolate reductase.<sup>
<xref ref-type="bibr" rid="bibr3-0897190012442717">3</xref>
</sup> Dihydrofolate reductase catalyzes the reaction of 7,8-dihydrofolate and nicotinamide adenine dinucleotide phosphate (NADP) to form 5,6,7,8-tetrahydrofolate and NADP<sup>+</sup>. Inhibition of dihydrofolate reductase blocks the formation of nucleotide precursors and prevents the production of DNA, RNA, and proteins (<xref ref-type="fig" rid="fig1-0897190012442717">Figure 1</xref>). Methotrexate can also inhibit thymidylate synthesis and the transport of reduced folates into the cell via polyglutamated methotrexate.<sup>
<xref ref-type="bibr" rid="bibr4-0897190012442717">4</xref>
</sup> The polyglutamated molecules are long-lived metabolites that retain some of the antifolate activities of the parent compound, although the result of inhibiting various folate-dependent enzymes is shifted to the inactivation of cell-signaling and transport processes.<sup>
<xref ref-type="bibr" rid="bibr4-0897190012442717">4</xref>
</sup>
</p>
<fig id="fig1-0897190012442717" position="float">
<label>Figure 1.</label>
<caption>
<p>Methotrexate mechanism of action. Methotrexate competitively and irreversibly inhibits dihydrofolate reductase, an enzyme that participates in tetrahydrofolate synthesis. The affinity of methotrexate for dihydrofolate reductase is about 1000-fold that of folate for dihydrofolate reductase. Dihydrofolate reductase catalyzes the conversion of dihydrofolate into the active tetrahydrofolate. Folic acid is needed for the de novo synthesis of the nucleoside, thymidine, required for DNA synthesis. Cytosolic folylpolyglutamate synthase adds glutamate residues to methotrexate to produce methotrexate polyglutamate. Because these larger and more hydrophilic metabolites are not substrates of folate-transport systems, they are retained by the cell, and the resulting increase in the intracellular methotrexate polyglutamate concentration increases the effectiveness of methotrexate. The addition of glutamate residues to methotrexate increases its affinity for other target enzymes (thymidylate synthetase) and enzymes of the de novo purine synthesis pathway. Other enzymes that are indirectly affected by methotrexate are 5,10-methylenetetrahydrofolate reductase and methylenetetrahydrofolate dehydrogenase. Methotrexate, therefore, inhibits the synthesis of DNA, RNA, thymidylates, and proteins (adapted with modifications from ref 4).</p>
</caption>
<graphic xlink:href="10.1177_0897190012442717-fig1.tif"/>
</fig>
<p>Methotrexate use in chemotherapy must be closely monitored due to its narrow therapeutic index.<sup>
<xref ref-type="bibr" rid="bibr5-0897190012442717">5</xref>
</sup> Side effects increase with dose escalation and frequency of administration and can include nausea, vomiting, headache, mucositis, dizziness, convulsions, nephrotoxicity, thrombocytopenia, and hepatitis.<sup>
<xref ref-type="bibr" rid="bibr6-0897190012442717">6</xref>
</sup> Methotrexate has 2 dose-limiting side effects, including bone marrow suppression (leukopenia, thrombocytopenia, and anemia) and gastrointestinal toxicity.<sup>
<xref ref-type="bibr" rid="bibr7-0897190012442717">7</xref>
</sup> In patients receiving therapy, vigilant monitoring is required to evaluate clearance of the drug. When doses higher than 100 mg/m<sup>2</sup> are given, leucovorin rescue is recommended to provide reduced folate to normal cells to bypass the metabolic block produced by high-dose methotrexate.<sup>
<xref ref-type="bibr" rid="bibr8-0897190012442717">8</xref>
</sup> Doses over 1 g are usually given with hydration, urinary alkalinization, and leucovorin to increase clearance and decrease nephrotoxicity.<sup>
<xref ref-type="bibr" rid="bibr9-0897190012442717">9</xref>
</sup>
</p>
<p>Several drugs interact with methotrexate including nonsteroidal anti-inflammatory drugs (NSAIDs), amoxicillin and co-trimoxazole (Table <xref ref-type="table" rid="table1-0897190012442717">1</xref>).<sup>
<xref ref-type="bibr" rid="bibr10-0897190012442717">10</xref>
<xref ref-type="bibr" rid="bibr11-0897190012442717"/>
<xref ref-type="bibr" rid="bibr12-0897190012442717"/>–<xref ref-type="bibr" rid="bibr13-0897190012442717">13</xref>
</sup> Drug interactions have been related to the additive effects of concurrent drug therapies, inhibition of renal excretion and tubular secretion of methotrexate, protein binding displacement with increased bioavailability, and inhibition of first-pass metabolism. The potential for drug interactions warrants close evaluation before starting chemotherapy with high-dose methotrexate and requires close monitoring of the patient and avoiding drugs identified as causing interactions if possible (Table <xref ref-type="table" rid="table1-0897190012442717">1</xref>).</p>
<table-wrap id="table1-0897190012442717" position="float">
<label>Table 1.</label>
<caption>
<p>Methotrexate Drug Interactions<sup><xref ref-type="table-fn" rid="table-fn2-0897190012442717">a</xref></sup>
</p>
</caption>
<graphic alternate-form-of="table1-0897190012442717" xlink:href="10.1177_0897190012442717-table1.tif"/>
<table>
<thead>
<tr>
<th>Class</th>
<th>Drug</th>
<th>Mechanism of action</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="4">NSAIDs</td>
</tr>
<tr>
<td>
</td>
<td>Aspirin</td>
<td>Displaces MTX from protein binding sites, decreases renal clearance</td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr13-0897190012442717">13</xref>,<xref ref-type="bibr" rid="bibr20-0897190012442717">20</xref>,<xref ref-type="bibr" rid="bibr71-0897190012442717">71</xref>
</sup>
</td>
</tr>
<tr>
<td> </td>
<td>Etodolac</td>
<td>Displaces MTX from protein binding sites, decreases renal clearance</td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr21-0897190012442717">21</xref>
</sup>
</td>
</tr>
<tr>
<td> </td>
<td>Flurbiprofen</td>
<td>Displaces MTX from protein binding sites, decreases renal clearance </td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr22-0897190012442717">22</xref>
</sup>
</td>
</tr>
<tr>
<td> </td>
<td>Ibuprofen</td>
<td>Displaces MTX from protein binding sites, decreases renal clearance </td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr12-0897190012442717">12</xref>
</sup>
</td>
</tr>
<tr>
<td>
</td>
<td>Indomethacin</td>
<td>Displaces MTX from protein binding sites, decreases renal clearance </td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr23-0897190012442717">23</xref>
</sup>
</td>
</tr>
<tr>
<td> </td>
<td>Ketoprofen</td>
<td>Displaces MTX from protein binding sites, decreases renal clearance </td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr24-0897190012442717">24</xref>,<xref ref-type="bibr" rid="bibr25-0897190012442717">25</xref>
</sup>
</td>
</tr>
<tr>
<td> </td>
<td>Naproxen</td>
<td>Displaces MTX from protein binding sites, decreases renal clearance </td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr26-0897190012442717">26</xref>
</sup>
</td>
</tr>
<tr>
<td> </td>
<td>Sulindac</td>
<td>Displaces MTX from protein binding sites, decreases renal clearance </td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr13-0897190012442717">13</xref>
</sup>
</td>
</tr>
<tr>
<td colspan="4">Antibiotics</td>
</tr>
<tr>
<td> </td>
<td>Trimethoprim-sulfamethoxazole </td>
<td>Displaces MTX from protein binding sites; or decreased renal elimination of MTX; or antifolate effect</td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr27-0897190012442717">27</xref>,<xref ref-type="bibr" rid="bibr28-0897190012442717">28</xref>
</sup>
</td>
</tr>
<tr>
<td> </td>
<td>Cephalosporins </td>
<td>Decreases renal elimination </td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr29-0897190012442717">29</xref>
</sup>
</td>
</tr>
<tr>
<td> </td>
<td>Ciprofloxacin</td>
<td>Possibly inhibits renal elimination</td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr30-0897190012442717">30</xref>,<xref ref-type="bibr" rid="bibr31-0897190012442717">31</xref>
</sup>
</td>
</tr>
<tr>
<td> </td>
<td>Doxycycline </td>
<td>Possibly inhibits renal elimination</td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr32-0897190012442717">32</xref>
</sup>
</td>
</tr>
<tr>
<td> </td>
<td>Penicillin</td>
<td>Decreases renal elimination </td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr33-0897190012442717">33</xref>,<xref ref-type="bibr" rid="bibr34-0897190012442717">34</xref>
</sup>
</td>
</tr>
<tr>
<td> </td>
<td>Amoxicillin</td>
<td>Decreases renal elimination </td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr35-0897190012442717">35</xref>
</sup>
</td>
</tr>
<tr>
<td> </td>
<td>Oxacillin</td>
<td>Decreases renal elimination </td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr36-0897190012442717">36</xref>
</sup>
</td>
</tr>
<tr>
<td> </td>
<td>Piperacillin/tazobactam</td>
<td>Decreases renal elimination </td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr37-0897190012442717">37</xref>
</sup>
</td>
</tr>
<tr>
<td> </td>
<td>Probenecid</td>
<td>Decreases plasma clearance; decreases hepatic excretion</td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr11-0897190012442717">11</xref>
</sup>
</td>
</tr>
<tr>
<td> </td>
<td>Vancomycin</td>
<td>Decreases renal clearance </td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr38-0897190012442717">38</xref>
</sup>
</td>
</tr>
<tr>
<td colspan="4">Proton pump inhibitors</td>
</tr>
<tr>
<td> </td>
<td>Omeprazole</td>
<td>Decreases renal elimination </td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr39-0897190012442717">39</xref>
<xref ref-type="bibr" rid="bibr40-0897190012442717"/>
<xref ref-type="bibr" rid="bibr41-0897190012442717"/>
<xref ref-type="bibr" rid="bibr42-0897190012442717"/>–<xref ref-type="bibr" rid="bibr43-0897190012442717">43</xref>
</sup>
</td>
</tr>
<tr>
<td> </td>
<td>Esomeprazole</td>
<td>Decreases renal elimination </td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr43-0897190012442717">43</xref>
</sup>
</td>
</tr>
<tr>
<td> </td>
<td>Pantoprazole</td>
<td>Decreases renal elimination </td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr43-0897190012442717">43</xref>,<xref ref-type="bibr" rid="bibr44-0897190012442717">44</xref>
</sup>
</td>
</tr>
<tr>
<td> </td>
<td>Lansoprazole</td>
<td>Decreases renal elimination </td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr43-0897190012442717">43</xref>
</sup>
</td>
</tr>
<tr>
<td colspan="4">Immunosuppressant</td>
</tr>
<tr>
<td> </td>
<td>Cyclosporine</td>
<td>Decreases metabolism </td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr45-0897190012442717">45</xref>
</sup>
</td>
</tr>
<tr>
<td colspan="3">Agents</td>
<td>
</td>
</tr>
<tr>
<td> </td>
<td>Radiographic contrast</td>
<td>Decreases renal clearance </td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr46-0897190012442717">46</xref>
</sup>
</td>
</tr>
<tr>
<td colspan="4">Vitamins</td>
</tr>
<tr>
<td> </td>
<td>Vitamin C</td>
<td>Decreases urinary pH, leading to decreased urinary elimination </td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr47-0897190012442717">47</xref>
</sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0897190012442717">
<p>Abbreviations: NSAIDs, nonsteroidal anti-inflammatory drugs; HD-MTX, high-dose methotrexate; MTX, methotrexate.</p>
</fn>
<fn id="table-fn2-0897190012442717">
<p>
<sup>a</sup>Several drug interactions have been noted with methotrexate or high-dose methotrexate, resulting in increased serum methotrexate levels and toxicity.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Recently, gene mutations in methylenetetrahydrofolate reductase have been shown to affect methotrexate serum levels and correlate with toxicity.<sup>
<xref ref-type="bibr" rid="bibr14-0897190012442717">14</xref>
</sup> Methylenetetrahydrofolate reductase regulates intracellular folate, playing a key role in cellular replication. In patients with methylenetetrahydrofolate reductase (<italic>MTHFR</italic>) gene variants C677T or A1298C, the translated enzyme has reduced functional capabilities with decreased catalytic function.<sup>
<xref ref-type="bibr" rid="bibr15-0897190012442717">15</xref>
<xref ref-type="bibr" rid="bibr16-0897190012442717"/>
<xref ref-type="bibr" rid="bibr17-0897190012442717"/>–<xref ref-type="bibr" rid="bibr18-0897190012442717">18</xref>
</sup> A recent retrospective study evaluated acute leukemia patients who were homozygous for the C677T mutation and undergoing maintenance chemotherapy with high-dose methotrexate. Patients who were homozygous for the MTHFR TT genotype had a higher cumulative incidence of combined hematopoietic and hepatic toxicity as compared with heterozygous and wild-type patients. Methotrexate toxicity occurred in 33.3% of the homozygous patients as compared with 4.7% of those without the mutation.<sup>
<xref ref-type="bibr" rid="bibr19-0897190012442717">19</xref>
</sup> Unfortunately, genetic testing has not evolved as a standard before the administration of high-dose methotrexate to identify individuals who may have an increased risk of methotrexate toxicity.</p>
<p>We report a case of methotrexate toxicity in a man treated for osteosarcoma, possibly due to an interaction with omeprazole. The patient had received high-dose methotrexate as part of his first chemotherapy cycle with no evidence of decreased methotrexate clearance. The patient was continued on omeprazole until his second round of chemotherapy which may have led to prolonged methotrexate levels and associated toxicity.</p>
</sec>
<sec id="section2-0897190012442717">
<title>Case Report</title>
<p>The patient was a 25-year-old man with a history of retinoblastoma diagnosed in 1983, treated with doxorubicin, cyclophosphamide, methotrexate, vincristine, and radiation. He was recently diagnosed with high-grade spindle cell carcinoma of the right sphenoid wing and underwent en bloc resection of the intradural and extradural sphenoid wing; however, local recurrence was detected on magnetic resonance imaging. The patient was admitted for his first cycle of neoadjuvant chemotherapy with cisplatin and doxorubicin followed by high-dose methotrexate with leucovorin rescue. He tolerated the first cycle of high-dose methotrexate at 12 g/m<sup>2</sup> (20 g) without any problems, with clearance levels at 24 hours of 3.11 µmol/L, 48 hours of 0.17 µmol/L, and at 63 hours with a level of 0.09 µmol/L. His urine pH was maintained at an alkaline pH to increase clearance and prevent accumulation of methotrexate. He was started on leucovorin 15 mg intravenously (IV) every 6 hours, followed by leucovorin 15 mg orally every 6 hours until the methotrexate level was less than 0.05 µmol/L, per institutional standards.<sup><xref ref-type="bibr" rid="bibr48-0897190012442717">48</xref></sup> Methotrexate clearance was determined to be adequate and he was discharged home. The patient was started on low-dose dexamethasone for a tension headaches after his first chemotherapy cycle and was switched from ranitidine to omeprazole for stress ulcer prophylaxis on discharge.</p>
<p>Patient was admitted to receive his second cycle of high-dose methotrexate and was continued on his previous discharge medications of dexamethasone, hydromorphone, and prochlorperazine. No other medications or herbals/vitamins were listed in the patient’s medication reconciliation sheet. Omeprazole was discontinued upon admission to the hospital, with the last dose of omeprazole being taken the day before the start of high-dose methotrexate. Omeprazole was replaced with lansoprazole for prophylaxis, based on a previous report that lansoprazole does not inhibit methotrexate clearance.<sup>
<xref ref-type="bibr" rid="bibr49-0897190012442717">49</xref>
</sup> After starting on high-dose methotrexate, the 24-hour methotrexate level was read at 245 µmol/L. The patient was continued on hydration and alkalinization, and leucovorin was increased to 120 mg/m<sup>2</sup> IV every 6 hours based on physician discretion and then increased to 500 mg/m<sup>2</sup> every 6 hours during the rest of his inpatient stay. The following afternoon, the patient had a grand mal seizure that resolved after treatment with lorazepam (2 doses of 1 mg each IV) correlating with the time of the recorded elevation of methotrexate. Computed tomography of the head was performed and results were negative for intracranial bleeding or stroke. The patient was transferred to the intensive care unit for seizure precaution with no further occurrences. Nephrology was consulted to evaluate the patient and dialysis was used in the interim until carboxypeptidase could be obtained. Carboxypetidase had to be obtained via a compassionate use program, for utilization from Protherics, Inc, West Conshohocken, PA. The drug was approved for use in this patient and the drug was approved for use with appropriate monitoring parameters for follow-up.</p>
<p>The patient’s serum creatinine increased from a baseline of 0.8 to 2.6 mg/dL 24 hours after the administration of methotrexate. High-flux hemodialysis was chosen for faster removal of fluid, increased rate of dialysate flow, and increased potential to remove toxin.<sup>
<xref ref-type="bibr" rid="bibr50-0897190012442717">50</xref>
</sup> The patient had high-flux hemodialysis for a 3-hour session to remove the serum methotrexate and a second session was planned for the next day. After the initial session of hemodialysis, the patient’s methotrexate level decreased only minimally and carboxypeptidase G2 was administered to further reduce methotrexate levels (<xref ref-type="fig" rid="fig2-0897190012442717">Figure 2</xref>). The patient’s methotrexate level did not drop significantly after the carboxypeptidase G2 was administered, with the level being recorded at 51.2 micromole/L before administration and 23.64 micromole/L thereafter (<xref ref-type="fig" rid="fig2-0897190012442717">Figure 2</xref>). The patient reported no adverse effects after the administration of carboxypeptidase G2 and urinary alkalinization and leucovorin rescue were continued throughout his course with intermittent cessation of bicarbonate if the urinary pH was <underline>≥</underline>8.0.</p>
<fig id="fig2-0897190012442717" position="float">
<label>Figure 2.</label>
<caption>
<p>Methotrexate elimination after high-dose methotrexate administration. The patient’s methotrexate level is depicted during his second cycle of chemotherapy with high-dose methotrexate. Arrows indicate time of hemodialysis and carboxypeptidase G2 administration.</p>
</caption>
<graphic xlink:href="10.1177_0897190012442717-fig2.tif"/>
</fig>
<p>The patient experienced grade III mucositis secondary to methotrexate (Table <xref ref-type="table" rid="table2-0897190012442717">2</xref>). The patient received a patient-controlled analgesic pump for mucositis and continued headaches and nystatin swish and swallow for oral thrush. He remained seizure free during his stay in the intensive care unit and was transferred back to the medical floor for further observation. The patient’s renal function was also affected, with serum creatinine increasing after methotrexate was initiated and resolving to his normal baseline values within 2 months. In addition, the patient had grade III thrombocytopenia that persisted throughout the course of his recovery.</p>
<table-wrap id="table2-0897190012442717" position="float">
<label>Table 2.</label>
<caption>
<p>Common Terminology Criteria for Adverse Events v4.0 (CTCAE)</p>
</caption>
<graphic alternate-form-of="table2-0897190012442717" xlink:href="10.1177_0897190012442717-table2.tif"/>
<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mucositis</td>
<td>Upper aerodigestive tract sites: minimal symptoms, normal diet; minimal respiratory symptoms not interfering with function</td>
<td>Upper aerodigestive tract sites: symptomatic but can eat and swallow a modified diet; respiratory symptoms interfering with function but not interfering with ADLs</td>
<td>Upper aerodigestive tract sites: symptomatic and unable to adequately eat or hydrate orally; respiratory symptoms interfering with ADLs</td>
<td>Symptoms associated with life-threatening consequences</td>
</tr>
<tr>
<td>Creatinine level</td>
<td>1.0-1.5 × ULN</td>
<td>&gt; 1.5-3.0 × ULN</td>
<td>&gt; 3.0-6.0 × ULN</td>
<td>&gt; 6.0 × ULN</td>
</tr>
<tr>
<td>Seizures</td>
<td align="center">–</td>
<td>One brief generalized seizure; seizures well-controlled by anticonvulsants; or infrequent focal motor seizures not interfering  with ADL</td>
<td>Seizures in which consciousness is altered; poorly controlled seizure disorder, with breakthrough generalized seizures despite medication</td>
<td>Seizures of any kind that are prolonged, repetitive, or difficult to control (eg, status epilepticus, intractable epilepsy)</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>&lt; LLN-75.0 × 10<sup>9</sup> /L</td>
<td>&lt; 75.0-50.0 × 10<sup>9</sup> /L</td>
<td>&lt; 50.0-25.0 × 10<sup>9</sup> /L</td>
<td>&lt; 25.0 × 10<sup>9</sup> /L</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0897190012442717">
<p>Abbreviations: ADLs, activities of daily living; LLN, lower limit of normal; ULN, upper limit of normal.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table3-0897190012442717" position="float">
<label>Table 3.</label>
<caption>
<p>Pharmacokinetic Properties of Proton Pump Inhibitors<sup><xref ref-type="bibr" rid="bibr51-0897190012442717">51</xref>,<xref ref-type="bibr" rid="bibr52-0897190012442717">52</xref></sup>
</p>
</caption>
<graphic alternate-form-of="table3-0897190012442717" xlink:href="10.1177_0897190012442717-table3.tif"/>
<table>
<thead>
<tr>
<th>PPI</th>
<th>Protein binding </th>
<th>Half-life</th>
<th>Bioavailability</th>
<th>Metabolism</th>
<th>Excretion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omeprazole</td>
<td>∼95%</td>
<td>0.5-1 h; in the elderly, 1 h</td>
<td>25%-40%</td>
<td>Hepatic, with major enzymes of CYP2C19 and 3A4</td>
<td>Fecal (18%-23%); renal (70%-77%)</td>
</tr>
<tr>
<td>Esomeprazole</td>
<td>97%</td>
<td>∼1-1.5 h</td>
<td>90%</td>
<td>Hepatic, with major enzymes of CYP2C19 and 3A4 </td>
<td>Urinary (80%, primarily as inactive metabolites; &lt;1% as active drug); fecal (20%)</td>
</tr>
<tr>
<td>Lansoprazole</td>
<td>97%</td>
<td>1.5 h; in the elderly, 1.9-2.9 h</td>
<td>80%-90%</td>
<td>Hepatic, with major enzymes of CYP2C19 and 3A4</td>
<td>Fecal (66%); renal (14%-25%)</td>
</tr>
<tr>
<td>Dexlansoprazole</td>
<td>96.1%-98.8%</td>
<td>1-2 h; in the elderly, 2.23 h</td>
<td>N/A</td>
<td>Hepatic, with major enzymes of CYCP2C19 and CYP3A</td>
<td>Fecal (47.6%); renal (50.7%) </td>
</tr>
<tr>
<td>Rabeprazole</td>
<td>∼96%</td>
<td>1-2 h</td>
<td>52%</td>
<td>Hepatic, with major enzymes of CYP3A and 2C19 </td>
<td>Fecal (10%); urinary (90% to inactive metabolites) </td>
</tr>
<tr>
<td>Pantoprazole</td>
<td>98% </td>
<td>1 h; in a slow metabolizer, 3.5-10 h</td>
<td>77%</td>
<td>Hepatic, with major enzymes of CYP2C19 and minor enzymes of CYP3A4, 2D6, and 2C9 </td>
<td>Fecal (18%); renal (71%)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0897190012442717">
<p>Abbreviations: PPI, proton pump inhibitor; N/A, not available.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section3-0897190012442717">
<title>Discussion</title>
<p>Methotrexate is a hydrophilic molecule that is only able to enter the cell through an active transport process. Once the molecule crosses the cell membrane, methotrexate is converted into the polyglutamated form (<xref ref-type="fig" rid="fig1-0897190012442717">Figure 1</xref>). This molecule is able to inhibit the transport of methotrexate outside the cells, allowing for retention inside the cell long after serum plasma levels of methotrexate have decreased.<sup>
<xref ref-type="bibr" rid="bibr1-0897190012442717">1</xref>
</sup> The half-life of methotrexate is relatively short, approximately 8 to 10 hours in a healthy patient. In some cases, adverse effects may continue for a day after serum levels decrease, due to the latent effects of the polyglutamated form. Methotrexate levels may also remain elevated if acute renal problems occur, as the drug is actively excreted through the kidney via tubular secretion. Several agents prolong methotrexate elimination in the renal tubules, including aspirin and probenecid.<sup>
<xref ref-type="bibr" rid="bibr53-0897190012442717">53</xref>,<xref ref-type="bibr" rid="bibr54-0897190012442717">54</xref>
</sup> However, several other drugs and herbal medications affect the clearance of methotrexate as well (Table <xref ref-type="table" rid="table1-0897190012442717">1</xref>).</p>
<p>The prevalence of methotrexate toxicity when using a high-dose regimen has varied over the years. In one study, mortality during treatment was estimated at approximately 6% (29 drug-related deaths in 498 patients).<sup>
<xref ref-type="bibr" rid="bibr54-0897190012442717">54</xref>
</sup> Mucositis occurs in up to 50% of patients.<sup>
<xref ref-type="bibr" rid="bibr55-0897190012442717">55</xref>
</sup> Nausea and vomiting are also common side effects in studies with single-agent chemotherapy, ranging from 5% to 60%. In studies using single-agent methotrexate, nephrotoxicity occurred in 20% to 40% of patients.<sup>
<xref ref-type="bibr" rid="bibr56-0897190012442717">56</xref>
</sup>
</p>
<p>In our patient, omeprazole was initially thought to cause an increase in serum methotrexate by inhibiting its elimination from the kidney. The proposed mechanism is believed to be due to omeprazole’s irreversible inhibition of the renal H<sup>+</sup>/K<sup>+</sup>-ATPase pump involved in methotrexate elimination.<sup>
<xref ref-type="bibr" rid="bibr57-0897190012442717">57</xref>,<xref ref-type="bibr" rid="bibr58-0897190012442717">58</xref>
</sup> Renal excretion of methotrexate is mediated by active transport into the distal tubule. The renal hydrogen pump acidifies the urine by pumping hydrogen ions into the tubule through cotransport with potassium. At urinary pH values of less than 6.0, omeprazole remains active. Inhibition of the ATPase pump leads to an accumulation of systemic methotrexate and numerous acute and delayed toxicities.<sup>
<xref ref-type="bibr" rid="bibr39-0897190012442717">39</xref>,<xref ref-type="bibr" rid="bibr40-0897190012442717">40</xref>
</sup> Several case reports have described an interaction between high-dose methotrexate and omeprazole. The first case report published showed that omeprazole delayed elimination of high-dose methotrexate, in which 1 patient had prolonged methotrexate levels while on omeprazole but not in subsequent cycles without the drug.<sup>
<xref ref-type="bibr" rid="bibr39-0897190012442717">39</xref>
</sup> However, Whelan and colleagues reported a case in which plasma methotrexate clearance was not affected in a patient receiving omeprazole.<sup>
<xref ref-type="bibr" rid="bibr59-0897190012442717">59</xref>
</sup> Nevertheless, subsequent case reports showed potential interaction between high-dose methotrexate and omeprazole.<sup>
<xref ref-type="bibr" rid="bibr40-0897190012442717">40</xref>,<xref ref-type="bibr" rid="bibr42-0897190012442717">42</xref>
</sup>
</p>
<p>A recent study evaluated the effect of proton pump inhibitors on the elimination of plasma methotrexate in 171 patients treated with high-dose methotrexate who received standard supportive care after treatment (ie, hydration, alkalinization, and leucovorin rescue). Proton pump inhibitor use delayed methotrexate clearance at 24, 48, and 72 hours after administration.<sup>
<xref ref-type="bibr" rid="bibr43-0897190012442717">43</xref>
</sup> However, the study failed to classify each of the proton pump inhibitors regarding their individual effect on methotrexate elimination.</p>
<p>In our patient, the effects of omeprazole lasted longer than 24 hours after the medication was discontinued. The inhibition of the renal H<sup>+</sup>/K<sup>+</sup>-ATPase pump in the kidney may last longer than omeprazole’s serum half-life, as this interaction seemed to have caused the decrease in methotrexate clearance. Omeprazole is predominately eliminated through the kidney and to a lesser extent in the bile. Other proton pump inhibitors of the benzimadazole class, such as lansoprazole, are mainly excreted in the bile and may have a decreased chance to bind to the renal pump. Several other factors may also contribute to omeprazole’s influence on methotrexate toxicity including inhibiting the efflux of methotrexate via the multidrug resistance protein (MRP3) or the competitive inhibition of transport with methotrexate through the human organic anion transport (hOAT) pathway in the proximal tubule.<sup>
<xref ref-type="bibr" rid="bibr41-0897190012442717">41</xref>,<xref ref-type="bibr" rid="bibr60-0897190012442717">60</xref>,<xref ref-type="bibr" rid="bibr61-0897190012442717">61</xref>
</sup> Further investigation into the inhibition of methotrexate clearance and binding affinity of proton pump inhibitors with their effect on methotrexate renal tubular secretion needs to be analyzed to derive what risk factors lead to prolonged methotrexate clearance. Understanding this information may provide evidence to support switching stress ulcer prophylactic medication from a proton pump inhibitor to a histamine 2 receptor antagonist such as ranitidine or famotidine, several days before high-dose methotrexate is administered.<sup>
<xref ref-type="bibr" rid="bibr62-0897190012442717">62</xref>
</sup> Since available evidence supports that proton pump inhibitors, specifically omeprazole, delay plasma methotrexate clearance in patients receiving high-dose methotrexate, further studies are needed to verify what factors (including concomitant drugs) predispose a patient to this risk.<sup>
<xref ref-type="bibr" rid="bibr43-0897190012442717">43</xref>
</sup>
</p>
<p>Acute renal failure induced by high-dose methotrexate is thought to be due to crystal precipitate formation of methotrexate in the distal convolute tubules. Patients with sustained and elevated plasma methotrexate levels have an increased risk of nephrotoxicity and increased morbidity.<sup>
<xref ref-type="bibr" rid="bibr63-0897190012442717">63</xref>
</sup> Hydration, urinary alkalinization, and leucovorin rescue have allowed for the continued use of high-dose methotrexate with reduced morbidity and mortality. However, there is always a risk for methotrexate toxicity in patients. The use of dialysis (including hemodialysis, high-flux hemodialysis, and charcoal hemofiltration) for varying durations (2 hours to 14 days) has been described in several case reports for removing high levels of serum methotrexate from patients.<sup>
<xref ref-type="bibr" rid="bibr64-0897190012442717">64</xref>
</sup>Methotrexate levels decrease after dialysis; although only minimally with peritoneal dialysis and most effectively with hemofiltration with an average decrease in serum levels of 82%.<sup>
<xref ref-type="bibr" rid="bibr64-0897190012442717">64</xref>
<xref ref-type="bibr" rid="bibr65-0897190012442717"/>–<xref ref-type="bibr" rid="bibr66-0897190012442717">66</xref>
</sup>
</p>
<p>The caveat to using dialysis to decrease methotrexate levels is the risk of rebound of methotrexate levels secondary to tissue-bound drug being released into the serum. Patients often had an increase in their methotrexate level 3 to 7 hours after dialysis was stopped.<sup>
<xref ref-type="bibr" rid="bibr65-0897190012442717">65</xref>
</sup> The rebound effect after dialysis ranges from 20% to 100% of the previous methotrexate level. Unfortunately, guidelines for effective dialysis methods and duration have not been proposed. In our patient, the methotrexate level decreased by approximately 34% when hemodialysis was used. After hemodialysis was performed, there was a clear change in the elimination rate of methotrexate (<xref ref-type="fig" rid="fig2-0897190012442717">Figure 2</xref>). In these cases, the intracellular fraction of methotrexate may have been transported into the serum, leading to an increase in plasma serum methotrexate levels after hemodialysis. It would be interesting to ascertain what elements lead to the rebound effects of hemodialysis, as we may be able to employ other methods to decrease the delayed clearance of methotrexate. This would provide a unique window of opportunity to decrease the overall exposure of methotrexate while increasing the clearance of the drug.</p>
<p>Carboxypeptidases are a class of enzymes that hydrolyze the carboxylic acid terminal glutamate from folic acid.<sup>
<xref ref-type="bibr" rid="bibr66-0897190012442717">66</xref>
</sup> Carboxypeptidase G2 has been used in clinical trials in patients with methotrexate toxicity, as it is able to cleave and inactivate methotrexate, resulting in 4-deoxy-4-amino-N10-methylpteroic acid (DAMPA) and glutamate (<xref ref-type="fig" rid="fig3-0897190012442717">Figure 3</xref>). The option of using carboxypeptidase in patients with high-dose methotrexate provides another method to rescue patients from potential toxic side effects of the drug. Several studies have shown that carboxypeptidase G2 reduces methotrexate levels in patients after high-dose methotrexate administration, with approximately 97% of patients having a rapid decrease in methotrexate plasma levels after administration.<sup>
<xref ref-type="bibr" rid="bibr64-0897190012442717">64</xref>,<xref ref-type="bibr" rid="bibr67-0897190012442717">67</xref>
</sup>
</p>
<fig id="fig3-0897190012442717" position="float">
<label>Figure 3.</label>
<caption>
<p>Carboxypeptidase G2 rapidly converts methotrexate into less toxic metabolites, causing a rapid decline in serum methotrexate levels. Carboxypeptidase G2 provides another option for patients receiving high-dose methotrexate that may circumvent life-threatening toxicity if methotrexate intoxication occurs. DAMPA indicates 4-deoxy-4-amino-N10-methylpteroic acid (taken with permission from Protherics, Inc).</p>
</caption>
<graphic xlink:href="10.1177_0897190012442717-fig3.tif"/>
</fig>
<p>In patients with acute renal failure secondary to high-dose methotrexate, carboxypeptidase G2 is considered safe.<sup>
<xref ref-type="bibr" rid="bibr68-0897190012442717">68</xref>,<xref ref-type="bibr" rid="bibr69-0897190012442717">69</xref>
</sup> The decrease in methotrexate levels after administration of carboxypeptidase G2 range from 77% to 91%, with subsequent second doses leading to further decreased levels.<sup>
<xref ref-type="bibr" rid="bibr64-0897190012442717">64</xref>
</sup> In our patient, the use of carboxypeptidase G2 was essential in decreasing methotrexate levels while decreasing further risk of methotrexate toxicity during his delayed clearance. Although the methotrexate level decreased, the change was lower than that previously reported with only a 54% decrease. Moreover, the elimination half-life decreased from the previous hour. Even though the patient did have a decrease in his serum methotrexate level, the change in his elimination of the drug may have been due to the molecular size of carboxypeptidase G2 and its inherent inability to cross into cells due to its molecular size.<sup>
<xref ref-type="bibr" rid="bibr69-0897190012442717">69</xref>
</sup>
</p>
<p>The use of the carboxypeptidase G2 in patients receiving high-dose methotrexate, specifically those with renal failure, has shown a potential in reducing further nephrotoxicity and preventing progressive renal failure. In numerous studies, patients treated with carboxypeptidase G2 had a return to baseline serum creatinine, in an average of 22 days after administration.<sup>
<xref ref-type="bibr" rid="bibr67-0897190012442717">67</xref>
</sup> The potential added effect of carboxypeptidase G2 may be due its value in preventing chronic renal failure in patients with acute renal failure in the face of high-dose methotrexate toxicity. In our patient, the use of carboxypeptidase may have provided nephroprotective effects by allowing for decreased methotrexate exposure in the renal tubules.<sup>
<xref ref-type="bibr" rid="bibr69-0897190012442717">69</xref>
</sup>
</p>
<p>The Naranjo adverse drug reaction probability scale is a generally accepted method for systematically assessing the probability of an adverse drug reaction in a clinical setting; factors such as temporal association of drug administration and event occurrence, alternative causes for the event, drug levels, dose–response relationships, and previous patient experience with the medication.<sup>
<xref ref-type="bibr" rid="bibr70-0897190012442717">70</xref>
</sup> Probability is assigned by a scoring system, indicating a doubtful, possible, probable, or definite relationship between the offending agent and the reaction. Based on the Naranjo scale, this case was considered to be a probable adverse reaction (score of 6) with the use of omperazole and methotrexate, we believe that this was a drug–drug interaction case and is consistent with previous reports.</p>
</sec>
<sec id="section4-0897190012442717">
<title>Conclusion</title>
<p>We report a case of methotrexate nephrotoxicity in a patient who discontinued omeprazole 24 hours before the initiation of high-dose methotrexate. The apparent correlation of delayed clearance may be due to the irreversible binding of omeprazole to the H<sup>+</sup>/K<sup>+</sup>-ATPase pump in the renal tubules. The use of hemodialysis in this case may be a cause for concern, as the timing of hemodialysis and carboxypeptidase G2 may lead to a rebound increase in methotrexate. Further analysis into the timing of these procedures may be warranted in future cases to maximize clearance and minimize the patient’s hospital stay. Continued research into drug clearance and pharmacogenomics need to be evaluated to better understand when to discontinue medications before the administration of high-dose methotrexate.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0897190012442717">
<label>Declaration of Conflicting Interests</label>
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0897190012442717">
<label>Funding</label>
<p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0897190012442717">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bleyer</surname>
<given-names>WA</given-names>
</name>
</person-group>. <article-title>The clinical pharmacology of methotrexate: new applications of an old drug</article-title>. <source>Cancer</source>. <year>1978</year>;<volume>41</volume>(<issue>1</issue>):<fpage>36</fpage>–<lpage>51</lpage>.</citation>
</ref>
<ref id="bibr2-0897190012442717">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schalhorn</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sauer</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wilmanns</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group> <article-title>Methotrexate and methotrexate polyglutamates in human sarcoma metastases after high-dose methotrexate therapy</article-title>. <source>Klin Wochenschr</source>. <year>1983</year>;<volume>61</volume>(<issue>21</issue>):<fpage>1089</fpage>–<lpage>1094</lpage>.</citation>
</ref>
<ref id="bibr3-0897190012442717">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frei</surname>
<given-names>E</given-names>
<suffix>3rd</suffix>
</name>
<name>
<surname>Blum</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Pitman</surname>
<given-names>SW</given-names>
</name>
<etal/>
</person-group> <article-title>High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity</article-title>. <source>Am J Med</source>. <year>1980</year>;<volume>68</volume>(<issue>3</issue>):<fpage>370</fpage>–<lpage>376</lpage>.</citation>
</ref>
<ref id="bibr4-0897190012442717">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chabner</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Allegra</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Curt</surname>
<given-names>GA</given-names>
</name>
<etal/>
</person-group> <article-title>Polyglutamation of methotrexate. Is methotrexate a prodrug?</article-title> <source>J Clin Invest</source>. <year>1985</year>;<volume>76</volume>(<issue>3</issue>):<fpage>907</fpage>–<lpage>912</lpage>.</citation>
</ref>
<ref id="bibr5-0897190012442717">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmiegelow</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Advances in individual prediction of methotrexate toxicity: a review</article-title>. <source>Br J Haematol</source>. <year>2009</year>;<volume>146</volume>(<issue>5</issue>):<fpage>489</fpage>–<lpage>503</lpage>.</citation>
</ref>
<ref id="bibr6-0897190012442717">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKendry</surname>
<given-names>RJ</given-names>
</name>
</person-group>. <article-title>The remarkable spectrum of methotrexate toxicities</article-title>. <source>Rheum Dis Clin North Am</source>. <year>1997</year>;<volume>23</volume>(<issue>4</issue>):<fpage>939</fpage>–<lpage>954</lpage>.</citation>
</ref>
<ref id="bibr7-0897190012442717">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takami</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kuniyoshi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Oomukai</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> <article-title>Severe complications after high-dose methotrexate treatment</article-title>. <source>Acta Oncol</source>. <year>1995</year>;<volume>34</volume>(<issue>5</issue>):<fpage>611</fpage>–<lpage>612</lpage>.</citation>
</ref>
<ref id="bibr8-0897190012442717">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Flombaum</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Meyers</surname>
<given-names>PA</given-names>
</name>
</person-group>. <article-title>High-dose leucovorin as sole therapy for methotrexate toxicity</article-title>. <source>J Clin Oncol</source>. <year>1999</year>;<volume>17</volume>(<issue>5</issue>):<fpage>1589</fpage>–<lpage>1594</lpage>.</citation>
</ref>
<ref id="bibr9-0897190012442717">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sand</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Jacobsen</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Effect of urine pH and flow on renal clearance of methotrexate</article-title>. <source>Eur J Clin Pharmacol</source>. <year>1981</year>;<volume>19</volume>(<issue>6</issue>):<fpage>453</fpage>–<lpage>456</lpage>.</citation>
</ref>
<ref id="bibr10-0897190012442717">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balis</surname>
<given-names>FM</given-names>
</name>
</person-group>. <article-title>Pharmacokinetic drug interactions of commonly used anticancer drugs</article-title>. <source>Clin Pharmacokinet</source>. <year>1986</year>;<volume>11</volume>(<issue>3</issue>):<fpage>223</fpage>–<lpage>235</lpage>.</citation>
</ref>
<ref id="bibr11-0897190012442717">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Basin</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Escalante</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Beardmore</surname>
<given-names>TD</given-names>
</name>
</person-group>. <article-title>Severe pancytopenia in a patient taking low dose methotrexate and probenecid</article-title>. <source>J Rheumatol</source>. <year>1991</year>;<volume>18</volume>(<issue>4</issue>):<fpage>609</fpage>–<lpage>610</lpage>.</citation>
</ref>
<ref id="bibr12-0897190012442717">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cassano</surname>
<given-names>WF</given-names>
</name>
</person-group>. <article-title>Serious methotrexate toxicity caused by interaction with ibuprofen</article-title>. <source>Am J Pediatr Hematol Oncol</source>. <year>1989</year>;<volume>11</volume>(<issue>4</issue>):<fpage>481</fpage>–<lpage>482</lpage>.</citation>
</ref>
<ref id="bibr13-0897190012442717">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Furst</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Herman</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Koehnke</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group> <article-title>Effect of aspirin and sulindac on methotrexate clearance</article-title>. <source>J Pharm Sci</source>. <year>1990</year>;<volume>79</volume>(<issue>9</issue>):<fpage>782</fpage>–<lpage>786</lpage>.</citation>
</ref>
<ref id="bibr14-0897190012442717">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Toffoli</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Veronesi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Boiocchi</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF)</article-title>. <source>Ann Oncol</source>. <year>2000</year>;<volume>11</volume>(<issue>3</issue>):<fpage>373</fpage>–<lpage>374</lpage>.</citation>
</ref>
<ref id="bibr15-0897190012442717">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herrlinger</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Barnardo</surname>
<given-names>MC</given-names>
</name>
<etal/>
</person-group> <article-title>The pharmacogenetics of methotrexate in inflammatory bowel disease</article-title>. <source>Pharmacogenet Genomics</source>. <year>2005</year>;<volume>15</volume>(<issue>10</issue>):<fpage>705</fpage>–<lpage>711</lpage>.</citation>
</ref>
<ref id="bibr16-0897190012442717">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muller</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kralovánszky</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Adleff</surname>
<given-names>V</given-names>
</name>
<etal/>
</person-group> <article-title>Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677 T polymorphism</article-title>. <source>Anticancer Res</source>. <year>2008</year>;<volume>28</volume>(<issue>5B</issue>):<fpage>3051</fpage>–<lpage>3054</lpage>.</citation>
</ref>
<ref id="bibr17-0897190012442717">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ulrich</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Yasui</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Storb</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group> <article-title>Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677 T polymorphism</article-title>. <source>Blood</source>. <year>2001</year>;<volume>98</volume>(<issue>1</issue>):<fpage>231</fpage>–<lpage>234</lpage>.</citation>
</ref>
<ref id="bibr18-0897190012442717">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Ede</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Laan</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Blom</surname>
<given-names>HJ</given-names>
</name>
<etal/>
</person-group> <article-title>Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity</article-title>. <source>Semin Arthritis Rheum</source>. <year>1998</year>;<volume>27</volume>(<issue>5</issue>):<fpage>277</fpage>–<lpage>292</lpage>.</citation>
</ref>
<ref id="bibr19-0897190012442717">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chiusolo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Reddiconto</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Casorelli</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group> <article-title>Preponderance of methylenetetrahydrofolate reductase C677 T homozygosity among leukemia patients intolerant to methotrexate</article-title>. <source>Ann Oncol</source>. <year>2002</year>;<volume>13</volume>(<issue>12</issue>):<fpage>1915</fpage>–<lpage>1918</lpage>.</citation>
</ref>
<ref id="bibr20-0897190012442717">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seideman</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Müller-Suur</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Renal effects of aspirin and low dose methotrexate in rheumatoid arthritis</article-title>. <source>Ann Rheum Dis</source>. <year>1993</year>;<volume>52</volume>(<issue>8</issue>):<fpage>613</fpage>–<lpage>615</lpage>.</citation>
</ref>
<ref id="bibr21-0897190012442717">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anaya</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Fabre</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bressolle</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group> <article-title>Effect of etodolac on methotrexate pharmacokinetics in patients with rheumatoid arthritis</article-title>. <source>J Rheumatol</source>. <year>1994</year>;<volume>21</volume>(<issue>2</issue>):<fpage>203</fpage>–<lpage>208</lpage>.</citation>
</ref>
<ref id="bibr22-0897190012442717">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tracy</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Worster</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bradley</surname>
<given-names>JD</given-names>
</name>
<etal/>
</person-group> <article-title>Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis</article-title>. <source>Br J Clin Pharmacol</source>. <year>1994</year>;<volume>37</volume>(<issue>5</issue>):<fpage>453</fpage>–<lpage>456</lpage>.</citation>
</ref>
<ref id="bibr23-0897190012442717">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maiche</surname>
<given-names>AG</given-names>
</name>
</person-group>. <article-title>Acute renal failure due to concomitant action of methotrexate and indomethacin</article-title>. <source>Lancet</source>. <year>1986</year>;<volume>1</volume>(<issue>8494</issue>):<fpage>1390</fpage>.</citation>
</ref>
<ref id="bibr24-0897190012442717">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thyss</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Milano</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kubar</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen</article-title>. <source>Lancet</source>. <year>1986</year>;<volume>1</volume>(<issue>8475</issue>):<fpage>256</fpage>–<lpage>258</lpage>.</citation>
</ref>
<ref id="bibr25-0897190012442717">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perrin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Milano</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Thyss</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>Biochemical and pharmacological consequences of the interaction between methotrexate and ketoprofen in the rabbit</article-title>. <source>Br J Cancer</source>. <year>1990</year>;<volume>62</volume>(<issue>5</issue>):<fpage>736</fpage>–<lpage>741</lpage>.</citation>
</ref>
<ref id="bibr26-0897190012442717">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Malaviya</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Pandey</surname>
<given-names>JN</given-names>
</name>
<etal/>
</person-group> <article-title>Fatal interaction between methotrexate and naproxen</article-title>. <source>Lancet</source>. <year>1986</year>;<volume>1</volume>(<issue>8494</issue>):<fpage>1390</fpage>.</citation>
</ref>
<ref id="bibr27-0897190012442717">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomas</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Gutterman</surname>
<given-names>LA</given-names>
</name>
</person-group>. <article-title>Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole</article-title>. <source>J Rheumatol</source>. <year>1986</year>;<volume>13</volume>(<issue>2</issue>):<fpage>440</fpage>–<lpage>441</lpage>.</citation>
</ref>
<ref id="bibr28-0897190012442717">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frain</surname>
<given-names>JB</given-names>
</name>
</person-group>. <article-title>Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole</article-title>. <source>J Rheumatol</source>. <year>1987</year>;<volume>14</volume>(<issue>1</issue>):<fpage>176</fpage>–<lpage>177</lpage>.</citation>
</ref>
<ref id="bibr29-0897190012442717">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iven</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Brasch</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Cephalosporins increase the renal clearance of methotrexate and 7-hydroxymethotrexate in rabbits</article-title>. <source>Cancer Chemother Pharmacol</source>. <year>1990</year>;<volume>26</volume>(<issue>2</issue>):<fpage>139</fpage>–<lpage>143</lpage>.</citation>
</ref>
<ref id="bibr30-0897190012442717">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dalle</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Auvrignon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vassal</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group> <article-title>Methotrexate-ciprofloxacin interaction: report of two cases of severe intoxication [in French]</article-title>. <source>Arch Pediatr</source>. <year>2001</year>;<volume>8</volume>(<issue>10</issue>):<fpage>1078</fpage>–<lpage>1081</lpage>.</citation>
</ref>
<ref id="bibr31-0897190012442717">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dalle</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Auvrignon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vassal</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group> <article-title>Interaction between methotrexate and ciprofloxacin</article-title>. <source>J Pediatr Hematol Oncol</source>. <year>2002</year>;<volume>24</volume>(<issue>4</issue>):<fpage>321</fpage>–<lpage>322</lpage>.</citation>
</ref>
<ref id="bibr32-0897190012442717">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tortajada-Ituren</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Ordovás-Baines</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Llopis Salvia</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group> <article-title>High-dose methotrexate-doxycycline interaction</article-title>. <source>Ann Pharmacother</source>. <year>1999</year>;<volume>33</volume>(<issue>7-8</issue>):<fpage>804</fpage>–<lpage>808</lpage>.</citation>
</ref>
<ref id="bibr33-0897190012442717">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nierenberg</surname>
<given-names>DW</given-names>
</name>
</person-group>. <article-title>Drug inhibition of penicillin tubular secretion: concordance between in vitro and clinical findings</article-title>. <source>J Pharmacol Exp Ther</source>. <year>1987</year>;<volume>240</volume>(<issue>3</issue>):<fpage>712</fpage>–<lpage>716</lpage>.</citation>
</ref>
<ref id="bibr34-0897190012442717">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dawson</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Abernethy</surname>
<given-names>VE</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>MP</given-names>
</name>
</person-group>. <article-title>Methotrexate and penicillin interaction [comment]</article-title>. <source>Br J Rheumatol</source>. <year>1998</year>;<volume>37</volume>(<issue>7</issue>):<fpage>807</fpage>.</citation>
</ref>
<ref id="bibr35-0897190012442717">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ronchera</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Hernández</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Peris</surname>
<given-names>JE</given-names>
</name>
<etal/>
</person-group> <article-title>Pharmacokinetic interaction between high-dose methotrexate and amoxycillin</article-title>. <source>Ther Drug Monit</source>. <year>1993</year>;<volume>15</volume>(<issue>5</issue>):<fpage>375</fpage>–<lpage>379</lpage>.</citation>
</ref>
<ref id="bibr36-0897190012442717">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Titier</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lagrange</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Péhourcq</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group> <article-title>Pharmacokinetic interaction between high-dose methotrexate and oxacillin</article-title>. <source>Ther Drug Monit</source>. <year>2002</year>;<volume>24</volume>(<issue>4</issue>):<fpage>570</fpage>–<lpage>572</lpage>.</citation>
</ref>
<ref id="bibr37-0897190012442717">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zarychanski</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wlodarczyk</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ariano</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group> <article-title>Pharmacokinetic interaction between methotrexate and piperacillin/tazobactam resulting in prolonged toxic concentrations of methotrexate</article-title>. <source>J Antimicrob Chemother</source>. <year>2006</year>;<volume>58</volume>(<issue>1</issue>):<fpage>228</fpage>–<lpage>230</lpage>.</citation>
</ref>
<ref id="bibr38-0897190012442717">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blum</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Seymour</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Toner</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Significant impairment of high-dose methotrexate clearance following vancomycin administration in the absence of overt renal impairment</article-title>. <source>Ann Oncol</source>. <year>2002</year>;<volume>13</volume>(<issue>2</issue>):<fpage>327</fpage>–<lpage>330</lpage>.</citation>
</ref>
<ref id="bibr39-0897190012442717">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reid</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yuen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Catalico</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Impact of omeprazole on the plasma clearance of methotrexate</article-title>. <source>Cancer Chemother Pharmacol</source>. <year>1993</year>;<volume>33</volume>(<issue>1</issue>):<fpage>82</fpage>–<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr40-0897190012442717">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beorlegui</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Aldaz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ortega</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>Potential interaction between methotrexate and omeprazole</article-title>. <source>Ann Pharmacother</source>. <year>2000</year>;<volume>34</volume>(<issue>9</issue>):<fpage>1024</fpage>–<lpage>1027</lpage>.</citation>
</ref>
<ref id="bibr41-0897190012442717">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Breedveld</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zelcer</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Pluim</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group> <article-title>Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions</article-title>. <source>Cancer Res</source>. <year>2004</year>;<volume>64</volume>(<issue>16</issue>):<fpage>5804</fpage>–<lpage>5811</lpage>.</citation>
</ref>
<ref id="bibr42-0897190012442717">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bauters</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>Verlooy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Robays</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group> <article-title>Interaction between methotrexate and omeprazole in an adolescent with leukemia: a case report</article-title>. <source>Pharm World Sci</source>. <year>2008</year>;<volume>30</volume>(<issue>4</issue>):<fpage>316</fpage>–<lpage>318</lpage>.</citation>
</ref>
<ref id="bibr43-0897190012442717">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suzuki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Doki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Homma</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy</article-title>. <source>Br J Clin Pharmacol</source>. <year>2009</year>;<volume>67</volume>(<issue>1</issue>):<fpage>44</fpage>–<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr44-0897190012442717">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tröger</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Stötzel</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Martens-Lobenhoffer</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Drug points: severe myalgia from an interaction between treatments with pantoprazole and methotrexate</article-title>. <source>BMJ</source>. <year>2002</year>;<volume>324</volume>(<issue>7352</issue>):<fpage>1497</fpage>.</citation>
</ref>
<ref id="bibr45-0897190012442717">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Korstanje</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>van Breda Vriesman</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>van de Staak</surname>
<given-names>WJ</given-names>
</name>
</person-group>. <article-title>Cyclosporine and methotrexate: a dangerous combination</article-title>. <source>J Am Acad Dermatol</source>. <year>1990</year>;<volume>23</volume>(<issue>2 pt 1</issue>):<fpage>320</fpage>–<lpage>321</lpage>.</citation>
</ref>
<ref id="bibr46-0897190012442717">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harned</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Mascarenhas</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Severe methotrexate toxicity precipitated by intravenous radiographic contrast</article-title>. <source>J Pediatr Hematol Oncol</source>. <year>2007</year>;<volume>29</volume>(<issue>7</issue>):<fpage>496</fpage>–<lpage>499</lpage>.</citation>
</ref>
<ref id="bibr47-0897190012442717">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sketris</surname>
<given-names>IS</given-names>
</name>
<name>
<surname>Farmer</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Fraser</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Effect of vitamin C on the excretion of methotrexate</article-title>. <source>Cancer Treat Rep</source>. <year>1984</year>;<volume>68</volume>(<issue>2</issue>):<fpage>446</fpage>–<lpage>447</lpage>.</citation>
</ref>
<ref id="bibr48-0897190012442717">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bleyer</surname>
<given-names>WA</given-names>
</name>
</person-group>. <article-title>New vistas for leucovorin in cancer chemotherapy</article-title>. <source>Cancer</source>. <year>1989</year>;<volume>63</volume>(<issue>6 suppl</issue>):<fpage>995</fpage>–<lpage>1007</lpage>.</citation>
</ref>
<ref id="bibr49-0897190012442717">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vakily</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Amer</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kukulka</surname>
<given-names>MJ</given-names>
</name>
<etal/>
</person-group> <article-title>Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis</article-title>. <source>J Clin Pharmacol</source>. <year>2005</year>;<volume>45</volume>(<issue>10</issue>):<fpage>1179</fpage>–<lpage>1186</lpage>.</citation>
</ref>
<ref id="bibr50-0897190012442717">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wall</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Johansen</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Molony</surname>
<given-names>DA</given-names>
</name>
<etal/>
</person-group> <article-title>Effective clearance of methotrexate using high-flux hemodialysis membranes</article-title>. <source>Am J Kidney Dis</source>. <year>1996</year>;<volume>28</volume>(<issue>6</issue>):<fpage>846</fpage>–<lpage>854</lpage>.</citation>
</ref>
<ref id="bibr51-0897190012442717">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sachs</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Howden</surname>
<given-names>CW</given-names>
</name>
</person-group>. <article-title>Review article: the clinical pharmacology of proton pump inhibitors</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2006</year>;<volume>23</volume>(<issue>suppl 2</issue>):<fpage>2</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr52-0897190012442717">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klotz</surname>
<given-names>U</given-names>
</name>
</person-group>. <article-title>Pharmacokinetic considerations in the eradication of <italic>Helicobacter pylori</italic>
</article-title>. <source>Clin Pharmacokinet</source>. <year>2000</year>;<volume>38</volume>(<issue>3</issue>):<fpage>243</fpage>–<lpage>270</lpage>.</citation>
</ref>
<ref id="bibr53-0897190012442717">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frenia</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>KS</given-names>
</name>
</person-group>. <article-title>Methotrexate and nonsteroidal antiinflammatory drug interactions</article-title>. <source>Ann Pharmacother</source>. <year>1992</year>;<volume>26</volume>(<issue>2</issue>):<fpage>234</fpage>–<lpage>237</lpage>.</citation>
</ref>
<ref id="bibr54-0897190012442717">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Von Hoff</surname>
<given-names>DD</given-names>
</name>
<name>
<surname>Penta</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Helman</surname>
<given-names>LJ</given-names>
</name>
<etal/>
</person-group> <article-title>Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration</article-title>. <source>Cancer Treat Rep</source>. <year>1977</year>;<volume>61</volume>(<issue>4</issue>):<fpage>745</fpage>–<lpage>748</lpage>.</citation>
</ref>
<ref id="bibr55-0897190012442717">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname>
<given-names>KK</given-names>
</name>
</person-group>. <article-title>Association of plasma methotrexate, neutropenia, hepatic dysfunction, nausea/vomiting and oral mucositis in children with cancer</article-title>. <source>Eur J Cancer Care (Engl)</source>. <year>2008</year>;<volume>17</volume>(<issue>3</issue>):<fpage>306</fpage>–<lpage>311</lpage>.</citation>
</ref>
<ref id="bibr56-0897190012442717">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ackland</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Schilsky</surname>
<given-names>RL</given-names>
</name>
</person-group>. <article-title>High-dose methotrexate: a critical reappraisal</article-title>. <source>J Clin Oncol</source>. <year>1987</year>;<volume>5</volume>(<issue>12</issue>):<fpage>2017</fpage>–<lpage>2031</lpage>.</citation>
</ref>
<ref id="bibr57-0897190012442717">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wingo</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Cain</surname>
<given-names>BD</given-names>
</name>
</person-group>. <article-title>The renal H-K-ATPase: physiological significance and role in potassium homeostasis</article-title>. <source>Ann Rev Physiol</source>. <year>1993</year>;<volume>55</volume>:<fpage>323</fpage>–<lpage>347</lpage>.</citation>
</ref>
<ref id="bibr58-0897190012442717">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kleinman</surname>
<given-names>JG</given-names>
</name>
</person-group>. <article-title>Proton ATPases and urinary acidification</article-title>. <source>J Am Soc Nephrol</source>. <year>1994</year>;<volume>5</volume>(<issue>5 suppl 1</issue>):<fpage>S6</fpage>–<lpage>S11</lpage>.</citation>
</ref>
<ref id="bibr59-0897190012442717">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Whelan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hoare</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Leonard</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Omeprazole does not alter plasma methotrexate clearance [comment]</article-title>. <source>Cancer Chemother Pharmacol</source>. <year>1999</year>;<volume>44</volume>(<issue>1</issue>):<fpage>88</fpage>–<lpage>89</lpage>.</citation>
</ref>
<ref id="bibr60-0897190012442717">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takeda</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Khamdang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Narikawa</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Characterization of methotrexate transport and its drug interaction with human organic ion transporters</article-title>. <source>J Pharmacol Exp Ther</source>. <year>2002</year>;<volume>302</volume>(<issue>2</issue>):<fpage>666</fpage>–<lpage>671</lpage>.</citation>
</ref>
<ref id="bibr61-0897190012442717">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hitzl</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zanger</surname>
<given-names>UM</given-names>
</name>
<etal/>
</person-group> <article-title>Influence of Omeprazole on multidrug resistance protein 3 expression in human liver</article-title>. <source>J Pharmacol Exp Ther</source>. <year>2003</year>;<volume>304</volume>(<issue>2</issue>):<fpage>524</fpage>–<lpage>530</lpage>.</citation>
</ref>
<ref id="bibr62-0897190012442717">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sartori</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Trevisani</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group> <article-title>Randomized trial of omeprazole or ranitidine versus placebo in the prevention of chemotherapy-induced gastroduodenal injury</article-title>. <source>J Clin Oncol</source>. <year>2000</year>;<volume>18</volume>(<issue>3</issue>):<fpage>463</fpage>–<lpage>467</lpage>.</citation>
</ref>
<ref id="bibr63-0897190012442717">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Comandone</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Passera</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Boglione</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>High dose methotrexate in adult patients with osteosarcoma: clinical and pharmacokinetic results</article-title>. <source>Acta Oncol</source>. <year>2005</year>;<volume>44</volume>(<issue>4</issue>):<fpage>406</fpage>–<lpage>411</lpage>.</citation>
</ref>
<ref id="bibr64-0897190012442717">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buchen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ngampolo</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Melton</surname>
<given-names>RG</given-names>
</name>
<etal/>
</person-group> <article-title>Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure</article-title>. <source>Br J Cancer</source>. <year>2005</year>;<volume>92</volume>(<issue>3</issue>):<fpage>480</fpage>–<lpage>487</lpage>.</citation>
</ref>
<ref id="bibr65-0897190012442717">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Widemann</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Balis</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Kempf-Bielack</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group> <article-title>High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma</article-title>. <source>Cancer</source>. <year>2004</year>;<volume>100</volume>(<issue>10</issue>):<fpage>2222</fpage>–<lpage>2232</lpage>.</citation>
</ref>
<ref id="bibr66-0897190012442717">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>DeAngelis</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>WP</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Carboxypeptidase G2 rescue after high-dose methotrexate</article-title>. <source>J Clin Oncol</source>. <year>1997</year>;<volume>14</volume>(<issue>7</issue>):<fpage>2145</fpage>–<lpage>2149</lpage>.</citation>
</ref>
<ref id="bibr67-0897190012442717">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Widemann</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Balis</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>RF</given-names>
</name>
<etal/>
</person-group> <article-title>Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction</article-title>. <source>J Clin Oncol</source>. <year>1997</year>;<volume>15</volume>(<issue>5</issue>):<fpage>2125</fpage>–<lpage>2134</lpage>.</citation>
</ref>
<ref id="bibr68-0897190012442717">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Phillips</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Balan</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group> <article-title>Pharmacokinetics of glucarpidase in subjects with normal and impaired renal function</article-title>. <source>J Clin Pharmacol</source>. <year>2008</year>;<volume>48</volume>(<issue>3</issue>):<fpage>279</fpage>–<lpage>284</lpage>.</citation>
</ref>
<ref id="bibr69-0897190012442717">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Widemann</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Hetherington</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>RF</given-names>
</name>
<etal/>
</person-group> <article-title>Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity</article-title>. <source>Cancer</source>. <year>1995</year>;<volume>76</volume>(<issue>3</issue>):<fpage>521</fpage>–<lpage>526</lpage>.</citation>
</ref>
<ref id="bibr70-0897190012442717">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naranjo</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Busto</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Sellers</surname>
<given-names>EM</given-names>
</name>
<etal/>
</person-group> <article-title>A method for estimating the probability of adverse drug reactions</article-title>. <source>Clin Pharmacol Ther</source>. <year>1981</year>;<volume>30</volume>(<issue>2</issue>):<fpage>239</fpage>–<lpage>245</lpage>.</citation>
</ref>
<ref id="bibr71-0897190012442717">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hayes</surname>
<given-names>AH</given-names>
<suffix>Jr</suffix>
</name>
</person-group>. <article-title>Therapeutic implications of drug interactions with acetaminophen and aspirin</article-title>. <source>Arch Intern Med</source>. <year>1981</year>;<volume>141</volume>(<issue>3 spec no</issue>):<fpage>301</fpage>–<lpage>304</lpage>. </citation>
</ref>
</ref-list>
</back>
</article>